Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia

ClinicalTrials.gov ID

NCT07168850

Lead Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

34Estimated

Last Update Posted

Feb 11, 2026Actual

Start Date

Jan 27, 2025Actual

Primary Completion Date

Feb 28, 2027Estimated

Completion Date

Feb 28, 2027Estimated

Official Title

Focused Ultrasound Pallidotomy for Medication-Refractory Limb Dystonia (FUTURE Study)

Brief Summary

The goal of this clinical trial is to find out if a non-invasive procedure called focused ultrasound can safely and effectively treat limb dystonia in adults who have not improved with medications or botulinum toxin injections.

The main questions it aims to answer are:

• Does focused ultrasound reduce the severity of limb dystonia symptoms?
• Is the procedure safe and well tolerated?

Researchers will compare people who receive focused ultrasound treatment to those who receive a sham procedure (a look-alike procedure without active treatment) to see if the treatment works.

Focused ultrasound works by producing a very small (millimeter-size) lesion in a deep brain region. In this study, the lesion is located in a region called globus pallidus, which helps control movement.

Participants will:

• Be randomly assigned to one of two groups: focused ultrasound or sham
• Undergo a procedure using MRI and focused ultrasound to target a part of the brain called the globus pallidus
• Be followed for 6 months after treatment to assess changes in symptoms, quality of life, and brain function
• Participants in the sham group will be offered the real treatment after 3 months

This study may offer a new non-surgical treatment option for people with dystonia affecting the arm or leg, whose pharmacological control is unsatisfactory.

Detailed Description

The FUTURE study is a prospective, randomized, double-blind, sham-controlled, multicenter national clinical trial aimed at assessing the efficacy and safety of unilateral MR-guided focused ultrasound (MRgFUS) pallidotomy in patients with limb dystonia that is refractory to standard pharmacological treatments.

Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions, causing abnormal movements or postures. In many cases, focal or segmental dystonias affecting the limbs can be managed with oral medications and botulinum toxin (BoNT) injections. However, a subset of patients does not respond adequately to these treatments. For such individuals, surgical intervention may offer relief, yet it remains underutilized due to concerns about invasiveness and complications.

Recent advancements in non-invasive neurosurgical techniques have introduced MRgFUS pallidotomy, a procedure that uses focused ultrasound beams under real-time MRI guidance to precisely ablate small brain targets-in this case, the globus pallidus internus (GPi). The FUTURE study specifically explores this technique as a less invasive alternative to deep brain stimulation, especially for patients with focal or segmental limb dystonia who are ineligible or reluctant to undergo conventional surgery.

The trial will enroll 34 adult patients with idiopathic or genetic limb dystonia that has proven resistant to pharmacologic and BoNT treatment. These patients will be randomly assigned in a 1:1 ratio to either:

• an active treatment group, undergoing unilateral GPi lesioning via MRgFUS,
• or a sham control group, receiving the same procedural setup but without therapeutic sonications.

At three months post-randomization, all patients in the sham group will cross over to receive the active MRgFUS treatment, allowing within-subject comparisons while ensuring ethical access to the therapeutic intervention. The follow-up period for each patient will last six months after active treatment, totaling a maximum of nine months of participation.

The primary endpoint is the change in motor severity as measured by the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) at three months post-treatment. Secondary endpoints include adverse event frequency, patient and clinician global impressions of change, disability assessments (e.g., QuickDASH), quality of life (SF-36), and neurocognitive testing.

Additionally, the study will incorporate neurophysiological (TMS) and neuroimaging (resting-state fMRI) techniques to investigate treatment-induced changes in cortical excitability, plasticity, and functional connectivity, providing insight into the neural mechanisms underlying clinical improvement.

The FUTURE study is coordinated by the Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy with participation from other three major Italian neurological institutes. It represents a pioneering effort to evaluate focused ultrasound as a non-invasive therapeutic option for patients with disabling and treatment-resistant forms of limb dystonia.

• Limb Dystonia
• Idiopathic Dystonia
• Medication-refractory Dystonia
• Dystonia, Focal

• Exablate MR-guided Focused Ultrasound Pallidotomy
• Sham Sham Exablate MRgFUS Pallidotomy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age 18-80 years
• Able and willing to consent and attend visits
• Idiopathic or hereditary limb dystonia (focal, segmental, or multifocal; isolated or combined)
• Refractory to oral therapy and botulinum toxin
• Stable medication for ≥30 days and ≥90 days since last BoNT
• Capable of communicating during Exablate procedure

Exclusion Criteria:

• Acquired secondary dystonia
• Dementia or other neurodegenerative disorders
• Any clinically significant or unstable medical condition, which, in the opinion of the principal investigator or the clinician delegated by the principal investigator, may put the participant at risk when participating in the study (e.g., unstable heart disease or coagulopathy; uncontrolled psychiatric comorbidity)
• Prior deep brain stimulation or other brain surgery
• Any contraindication to MRI
• Skull Density Ratio (SDR) < 0.40
• Significant brain lesions (eg brain tumor, significant white matter lesions or globus pallidus interna lesions on baseline MRI)
• Pregnancy

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER

Collaborators

Azienda ULSS 3 SerenissimaOTHER

IRCCS Centro Neurolesi Bonino PulejoOTHER

Azienda Ospedaliera Villa SofiaUNKNOWN

silvia.marino@irccsme.it

• Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects

  NCT06036199

  RecruitingInterventionalNot ApplicableUpdated Jun 11, 2026
• Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders

  NCT01698450

  CompletedInterventionalPhase 1Updated Oct 9, 2014
• MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD)

  NCT06367608

  RecruitingInterventionalNot ApplicableUpdated Feb 27, 2026
• Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.

  NCT07764874

  Not yet recruitingInterventionalNot ApplicableUpdated Aug 24, 2026
• ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

  NCT02252380

  Active, not recruitingInterventionalNot ApplicableUpdated May 1, 2025
• ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease

  NCT02347254

  Active, not recruitingInterventionalNot ApplicableUpdated May 1, 2025